Pharmacy cost sharing, antiplatelet therapy utilization, and health outcomes for patients with acute coronary syndrome

American Journal of Managed Care

Volumn 16, Issue 4, 2010, Pages 290-297

  Philipson, Tonnas J ^a   Mozaffari, Essy ^b   Maclean, John Ross ^c  

^a UNIVERSITY OF CHICAGO   (United States)

^b SANOFI   (France)

^c BRISTOL MYERS SQUIBB   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTITHROMBOCYTIC AGENT;

ACUTE CORONARY SYNDROME; AGED; ARTICLE; CORONARY STENT; FEMALE; HEALTH CARE COST; HOSPITAL ADMISSION; HOSPITAL READMISSION; HUMAN; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PATIENT COMPLIANCE; PHARMACY; PRESCRIPTION; PRIORITY JOURNAL; RETROSPECTIVE STUDY; TREATMENT OUTCOME; TREATMENT WITHDRAWAL;

ACUTE CORONARY SYNDROME; AGED; AGED, 80 AND OVER; COST SHARING; COST-BENEFIT ANALYSIS; FEMALE; FOLLOW-UP STUDIES; HEALTH BENEFIT PLANS, EMPLOYEE; HEALTH CARE COSTS; HOSPITALIZATION; HUMANS; MALE; MIDDLE AGED; OUTCOME AND PROCESS ASSESSMENT (HEALTH CARE); PLATELET AGGREGATION INHIBITORS; PRESCRIPTION FEES; RETROSPECTIVE STUDIES; STENTS; TICLOPIDINE; UNITED STATES;

EID: 77951551417     PISSN: 10880224     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (28)

1. Joyce GF, Escarce JJ, Solomon MD, Goldman DP. Employer drug benefit plans and spending on prescription drugs [published correction appears in JAWA 2002;288(19):2409]. JAWA 2002;288(14):1733-1739.
2. Goldman DP, Joyce GF, Zheng Y. Prescription drug cost sharing: associations with medication and medical utilization and spending and health. JAMA. 2007;298(1):61-69. (Pubitemid 47026771)
3. Huskamp H, Deverka P, Landrum M, Epstein R, McGuigan K. Effect of Incentive Formularies on Medication Continuation and Spending Among Elderly Retirees. Boston, MA: Academy Health; 2006.
4. Chandra A, Gruber J, McKnight R. Patient Cost-Sharing, Hospitalization Offsets, and the Design of Optimal Health Insurance for the Elderly. Cambridge, MA: National Bureau of Economic Research lnc; 2007. NBER working paper 12972.
5. Lichtenberg FR. Do (more and better) drugs keep people out of hospitals? Am Econ Rev. 1996;86(2):384-388.
6. Lichtenberg FR. Are the benefits of newer drugs worth their cost? Evidence from the 1996 MEPS. Health Aff (Millwood). 2001;20(5):241-251.
7. Goldman DP, Joyce GF, Karaca-Mandic P, Varying pharmacy benefits with clinical status: the case of cholesterol-lowering therapy. Am J Manag Care. 2006;12(1):21-28. (Pubitemid 43139537)
8. Colombi AM, Yu-Isenberg K, Priest J. The effects of health plan copayments on adherence to oral diabetes medication and health resource utilization. J Occup Environ Med. 2008;50(5):535-541. (Pubitemid 351677636)
9. Fendrick AM, Smith DG, Chemew ME, Shah SN. A benefit-based copay for prescription drugs: patient contribution based on total benefits, not drug acquisition cost. Am J Manag Care. 2001;7(9):861-867.
10. Fendrick AM, Chemew ME. Value-based insurance design: a "clinically sensitive" approach to preserve quality of care and contain costs. Am J Manag Care. 2006;12(1):18-20.
11. Chemew ME, Rosen AB, Fendrick AM. Value-based insurance design. Health Aff (Millwood). 2007;26(2):w195-w203.
12. Lloyd-Jones D, Adams R, Carnethon M, et al; American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics: 2009 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee [published correction appears in Circulation. 2009;119(3):e182]. Circulation. 2009;119(3):e21-e181.
13. Mehta SR, Yusuf S, Peters RJ, et al; Clopidogrel in Unstable Angina to Prevent Recurrent Events Trial (CURE) Investigators. Effects of pretreatment with Clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. Lancet. 2001;358(9281):527-533.
14. Steinhubl SR, Berger PB, Mann JT III, et al; CREDO Investigators (Clopidogrel for the Reduction of Events During Observation). Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial [published correction appears in JAMA. 2003;289(8):987]. JAMA 2002;288(19):2411-2420.
15. Braunwald E, Fauci AS, Kasper DL, Hauser SL, Longo DL, Jameson JL. Harrison's Principles of Internal Medicine. NewYork, NY: McGraw-Hill Professional Publishing; 2001.
16. Jackevicius CA, Tu JV, Demers V, et al. Cardiovascular outcomes after a change in prescription policy for Clopidogrel. N Engl J Med. 2008;359(17):1802-1810.
17. Avom J, Monette J, Lacour A, et al. Persistence of use of lipid-lowering medications: a cross-national study. JAMA. 1998;279(18):1458-1462. (Pubitemid 28228203)
18. Benner JS, Glynn RJ, Mogun H, Neumann PJ, Weinstein MC, Avom J. Long-term persistence in use of statin therapy in elderly patients. JAMA. 2002;288(4):455-461. (Pubitemid 34787476)
19. Howell N, Trotter R, Mottram DR, Rowe PH. Compliance with statins in primary care. Pharm J. 2004;272:23-26.
20. Insull W. The problem of compliance to cholesterol altering therapy. J Intern Med. 1997,241(4):317-325. (Pubitemid 27223997)
21. Schultz JS, O'Donnell JC, McDonough KL, Sasane R, Meyer J. Determinants of compliance with statin therapy and low-density lipoprotein cholesterol goal attainment in a managed care population. Am J Manag Care. 2005;11(5):306-312. (Pubitemid 40646935)
22. Sikka R, Xia F, Aubert RE. Estimating medication persistency using administrative claims data. Am J Manag Care. 2005;11(7):449-457. (Pubitemid 41022729)
23. Sokol MC, McGuigan KA, Verbrugge RR, Epstein RS. Impact of medication adherence on hospitalization risk and healthcare cost. Med Care. 2005;43(6):521-530.
24. Ho PM, Fihn SD, Wang L, et al. Clopidogrel and long-term outcomes after stent implantation for acute coronary syndrome. Am Heart J. 2007;154(5):846-851. (Pubitemid 350010928)
25. Klepser DG, Huether JR, Handke LJ, Williams CE. Effect on drug utilization and expenditures of a cost-share change from copayment to coinsurance. J Manag Care Pharm. 2007;13(9):765-777.
26. Goldman DP, Joyce GF, Escarce JJ, et al. Pharmacy benefits and the use of drugs by the chronically ill. JAMA. 2004;291(19):2344-2350.
27. Chen ZM, Jiang LX, Chen YR et al; COMMIT (Clopidogrel and Metoprolol in Myocardial Infarction Trial) Collaborative Group. Addition of Clopidogrel to aspirin in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial. Lancet. 2005:366(9497):1607-1621.
28. Sabatine MS, Cannon CP, Gibson CM, et al; CLARITY-TIMI 28 Investigators. Addition of Clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation. N Engl J Med. 2005;352(12):1179-1189.